Diagnostic reagents excluded from medicinal entry where statute plainly confined coverage to treatment goods.

Diagnostic reagents used in pathological testing were held not to fall within the sales tax entry for medicinal formulations or preparations ready for use in treatment, mitigation or prevention of disease. The Court treated diagnosis as distinct from treatment and noted that the relevant amendment had deliberately omitted diagnostic goods from the specific entry during the years in question; they therefore fell under the residuary entry. It also held that certificates and expert opinions could not control classification where the statutory language was clear and unambiguous. The evidence was rightly rejected for classification purposes because external material cannot expand the scope of a plain taxing entry.

---

---

Issues: (i) Whether diagnostic reagents manufactured and sold by the applicant during the relevant years were covered by Entry C-I-24 of Schedule C to the Bombay Sales Tax Act, 1959 or by the residuary Entry C-II-102; (ii) Whether the Tribunal was justified in discarding the evidence produced to show that such reagents were treated as goods used in treatment.

Issue (i): Whether diagnostic reagents manufactured and sold by the applicant during the relevant years were covered by Entry C-I-24 of Schedule C to the Bombay Sales Tax Act, 1959 or by the residuary Entry C-II-102.

Analysis: Entry C-I-24, as it stood during the relevant period, was confined to medicinal formulations or preparations ready for use, internally or externally, for treatment, mitigation or prevention of disease. The earlier scheme of the Act had separately dealt with medicines used for diagnosis as well as treatment, but after the 1981 amendment the words relating to diagnosis were excluded from the specific entry. The Court held that diagnosis and treatment, though closely connected, are not synonymous. Diagnostic reagents used in pathological laboratories are employed to detect disease and do not themselves constitute treatment of the patient. The Court also held that the later reintroduction of the words relating to diagnosis showed that the exclusion was deliberate and effective during the relevant years.

Conclusion: The diagnostic reagents were not covered by Entry C-I-24 and fell under the residuary Entry C-II-102; this issue was answered against the applicant and in favour of the revenue.

Issue (ii): Whether the Tribunal was justified in discarding the evidence produced to show that such reagents were treated as goods used in treatment.

Analysis: The certificates and expert opinions from doctors, laboratories and users were held to have no bearing on the classification once the statutory entry was found to be clear and unambiguous. The Court applied the principle that where the language of the entry is plain, classification must be decided by the words used in the statute and not by external material intended to enlarge the scope of the entry. The evidence could not override the express exclusion of goods used for diagnosis from the specific entry during the relevant period.

Conclusion: The Tribunal was justified in rejecting the evidence for classification purposes; this issue was also answered against the applicant and in favour of the revenue.

Final Conclusion: The specific taxing entry was held not to include diagnostic reagents during the relevant years, and the assessment was therefore upheld under the residuary entry.

Ratio Decidendi: Where a taxing entry is clear, its scope cannot be enlarged by treating diagnosis as synonymous with treatment or by relying on external evidence; exclusion of diagnostic goods from the specific entry must be given effect according to the statutory language.

---